Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Will Allow ANDA Corrections … Until 10 Minor Deficiencies Found

This article was originally published in The Pink Sheet Daily

Executive Summary

GDUFA refuse-to-receive draft guidance says that agency will allow sponsors to make a few small fixes to their applications, but FDA won’t accept any ANDAs that have big problems.

You may also be interested in...

FDA Sets New Goal For Biosimilar, Drug Promotion Guidances

Agency plans to issue 102 new and revised draft guidances this year, including those on use of multiple endpoints in clinical trials, 180-day exclusivity, and ANDA refuse-to-receive standards.

U.S. Generic Exclusivity Process To Go Public?

The U.S. FDA wants to know whether its 180-day generic exclusivity process should be revealed up front; the question will be one of many on ANDA reviews to be considered at a September public hearing.

ANDA Stability Requirements To Be Broadly Grandfathered, FDA Says

In a win-win for agency and industry, generic applications submitted before deadline for new stability requirements still will be judged by old standards, even if the ANDAs are amended or resubmitted.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts